[ad_1]
The conditional authorization covers adults and children aged 2 years and older with severe or life-threatening PIK3CA-related overgrowth disorders.
Medscape News Europe
[ad_2]
Source link : https://www.medscape.com/viewarticle/ema-backs-first-drug-severe-overgrowth-disorders-2026a1000gsu?src=rss
Author :
Publish date : 2026-05-22 14:46:00
Copyright for syndicated content belongs to the linked Source.